Publications by authors named "P G Schlegel"
Atrial Secondary Tricuspid Regurgitation: Insights Into the EuroTR Registry.
JACC Cardiovasc Interv
December 2024
Article Synopsis
- Atrial secondary tricuspid regurgitation (A-STR) is a subtype of secondary tricuspid regurgitation (STR) that is often treated with transcatheter tricuspid valve edge-to-edge repair (T-TEER), showing distinct patient characteristics and treatment outcomes.
- A study involving 641 patients revealed that 31% had A-STR, which was linked to better heart function, a higher presence of atrial fibrillation, and more effective TR reduction post-procedure compared to nonatrial STR patients.
- A-STR patients experienced improved survival rates and lower symptomatic burdens after treatment; only 38% remained symptomatic (NYHA class ≥III) after 2 years, compared to 46
Article Synopsis
- Stability is essential for using recombinant proteins in therapeutics and biotechnology, and deep learning methods like ProteinMPNN can help design and stabilize proteins.
- Despite these advancements, conventional designs still struggle to outperform the stability of natural proteins, particularly those from hyperthermophiles with unique amino acid compositions.
- The new model, HyperMPNN, effectively captures this unique composition and shows promise for designing highly thermostable proteins, achieving stability at much higher temperatures than previously possible.
Aims: Conventional parameters of right ventricular (RV) function are load-dependent and therefore do not accurately reflect contractility in patients with relevant tricuspid regurgitation (TR). RV adaptability to load has been characterized using the Dandel's index in patients with heart failure, but its prognostic value in patients undergoing tricuspid transcatheter edge-to-edge repair (T-TEER) has not been investigated so far.
Methods And Results: From the EuroTR registry (2019 to 2022), patients with complete datasets and a minimum of 2-years of follow-up were included.
Article Synopsis
- Treosulfan is an important treatment in allogeneic haematopoietic stem cell transplantation (allo-HSCT) for children, offering lower toxicity than traditional drugs.
- Researchers studied the effects of treosulfan on 83 pediatric patients to see how it impacts survival, graft failure, and graft-versus-host disease.
- The results showed no significant correlation between treosulfan exposure and clinical outcomes or toxicity, indicating that standardized dosing is effective for pediatric allo-HSCT.